The study will evaluate the safety and efficacy of dopamine neural precursor cell transplantation therapy derived from homogeneous embryonic stem cells in patients who have been diagnosed with Parkinson's disease for more than five years. The trial will take place at Severance Hospital in the first half of this year.
The study will evaluate the safety and efficacy of dopamine neural precursor cell transplantation therapy derived from homogeneous embryonic stem cells in patients who have been diagnosed with Parkinson's disease for more than five years. The trial will take place at Severance Hospital in the first half of this year.
Nicotinamide Exacerbates Motor Symptoms of Parkinson’s Disease in Mice
Follow up on Stem Cell therapy
